Radiopharm Theranostics Limited (RADX) Revenue History
Annual and quarterly revenue from 2021 to present
RADX Revenue Over Time (2021–2024)
RADX Revenue Growth History
3 of 3 years with positive growth- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- +3210.6%
- FY2023 revenue growth
- +2.3%
- FY2024 revenue growth
- +1114.3%
Revenue Breakdown
RADX's revenue distribution by segment and geography
By Geography
RADX Revenue Analysis (2021–2024)
Current Revenue & Growth
As of June 23, 2026, Radiopharm Theranostics Limited (RADX) generated trailing twelve-month (TTM) revenue of $0.
Historical Growth Trajectory
RADX's historical revenue data shows a 3-year CAGR of +643.8%. Radiopharm Theranostics Limited's highest annual revenue of $3.6 million was recorded in 2024, an all-time high.
Peer Comparison
Compared to Healthcare sector peers — including RNW (+36.9% YoY), LNTH (+0.6% YoY), and AGEN (+24.5% YoY). Compare RADX vs RNW →
RADX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RADXCurrent | $0 | - | - | -1050.6% | |
 RNW | $139.1B | +36.9% | +23.6% | 43.4% | |
 LNTH | $1.5B | +0.6% | +35.3% | 20.2% | |
 AGEN | $114M | +24.5% | +5.3% | -18.0% | |
 PRTC | $5M | -53.7% | -11.0% | -2114.7% |
RADX Historical Revenue Data (2021–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $3.6M | +1114.3% | $39K | 1.1% | $-38,173,865 | -1050.6% |
| 2023 | $299K | +2.3% | $299K | 100.0% | $-36,620,852 | -12238.4% |
| 2022 | $292K | +3210.6% | $292K | 100.0% | $-34,508,085 | -11803.3% |
| 2021 | $9K | - | $9K | 100.0% | $-19,916,352 | -225527.7% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RADX — Frequently Asked Questions
Quick answers to the most common questions about buying RADX stock.
Is RADX's revenue growth accelerating or slowing?
RADX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is RADX's revenue history from 2021 to 2026?
Radiopharm Theranostics Limited (RADX) revenue history spans 2021 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is RADX's long-term revenue growth rate (CAGR)?
Radiopharm Theranostics Limited's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for RADX.
Why does RADX's quarterly revenue fluctuate?
RADX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Radiopharm Theranostics Limited's revenue data from 2021 to 2026 shows full historical quarterly detail on this page.
How is RADX's revenue distributed by segment?
RADX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does RADX's revenue compare to industry peers?
Radiopharm Theranostics Limited (RADX) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.